FF
10.

11.

12.

13,

14.

15.

16.

17.

18.

19,

20.

21.

22.

23.

24.

Principal investigator/Program Director (Last, first, midale): Blanck, George
G. Blanck, D. Li, E. Pomert, B. Pollack, §. Chen. Multiple insertions and tandem repeats of origin minus SV40
DNA in transformed rat and mouse cells. J. Virol., 62, 1520-23 (1988).

G. Bianck and J. Strominger. Molecular organization of the DQ subregion (DO-DX-DV-DQ) of the human MHC
and its evolutionary implications. J. Immunol. 141, 1734-37 (1988).

T. Spies, G. Blanck, M. Bresnahan, J. Sands, and J. Strominger. A new cluster of genes within the human major
histocompatibility complex. Science, 243, 214-217 (1989).

G. Blanck,, M. Lok, K. Kok, E. Downie, J. Korn, and J. Strominger. IFN gamma induction of HLA class II
mRNAs in dermal fibroblasts studied by RNAse protection analysis. Human Immunol. 29, 150-156 (1990).

G. Bianck and J. Strominger. Cosmid clones in the HLA-DZ and DP subregions. Human Immunol. 27, 265-268
(1990).

T. Spies, M. Bresnahan, §. Bahram, D. Arnold, G. Blanck, E. Mellins, D. Pious, R. DeMars. A gene in thje
human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature
348: 744-747 (1990).

G. Blanck. Human Major Histocompatibility Complex: Genes and Diseases. J. Florida Med. Assoc. 79, 97-99
(1992).

Y. Lu, G. Ussery, M. Muncaster, B.Gallie and G. Blanck. Evidence for retinoblastoma (RB) protein dependent
and independent IFN-y responses. RB coordinately rescues IFN-y inducibility of MHC class II gene transcription
in noninducible breast carcinoma cells. Oncogene 9: 1015-1019 (1994).

Y. La, G. Ussery, M. Jacim, M. Tschickardt, J. Boss, and G. Blanck. Retinoblastoma protein regulation of
surface CD74 (invariant chain) expression in breast carcinoma cells. Mol. Immun. 31: 1365-1368 (1994).

M. E. Tschickardt, Y. Lu, M. Jacim, G. Ussery, V. Steimle, B. Mach and G. Blanck. RB and a novel E2F-1
binding protein in MHC class II deficient B-cell lines and normal IFN-y induction of the class II tcansactivator
CIITA in class HI noninducible RB-defective tumor lines. Int’|. J. Cancer 62: 461-465 (1995).

D. Berry, Y. Lu, P. Fallon, C. O’Connell, S. Hu, H, Xu and G. Blanck. Retinoblastoma protein inhibits IFN-y
induced apoptosis. Oncogene 12: 1809-1819 (1996).

Y. Lu, J. Boss, $. Hu, H. Xu and G. Blanck. Apoptosis independent, retinoblastoma protein rescue of HLA class IT
mRNA inducibility in non-small cell lung carcinoma cells: Lack of surface class II expression associated with a
specific defect in HLADRA induction. J. Immunol. 156: 2495-2502 (1996).

Y. Lu, B. Schmidt, M. Tschickardt and G. Blanck. A defect in IFN-y induction of CIITA, a common defect in
human tumor lines, prevents retinoblastoma protein rescue of HLA class II inducibility and allows mapping of
induction of apoptosis to the non-CIITA branch of the IFN-y signal transduction pathway. 1996 (in revision).

B. Schmidt, 8. S. Carter, D.E. Berry, and G. Blanck. Vitamin D3 reduces the apoptotic effect of IFN-y but does
not facilitate HLA class II inducibility in RB-defective cells. Cancer Let. 110: 169-176 (1996).

D. E. Berry, M. M. Haag, M. J. Sutcliffe, D. P. Dumont, and G. Blanck. 1996, Defective major histocompatibility
complex class II transactivator (CIITA) inducibility in human tumor lines is not due to gross CIITA gene defects or
chromosomal rearrangements. submitted for publication.

(24 total; nos. 1 and 8 deleted because of space limitations.)

a
PHS 398 (Rev. 5/95) (Form Page 6) Page FF
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.